Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by RENO911on Aug 05, 2019 11:51am

48 Views

Post# 29994721

RE:POSSIBLE ACQUISITION

STOCKGURU69 wrote: Facts. No plants , No extraction equipment, just a house, deal not closed, asking $2.1 million yet Kly paying $3.5 million (crazy) IF they find the cash. They are working on a retail website yet have not products. Smh. They need this like another hole in the managements heads. Stick with the facts kids.

PARTNERSHIP DESPERATELY NEEDED

Penny, you need to give it a break man. Every time you get banned you create a new account.. you're like a horse sht fly that just wont go away.

Bullboard Posts

Mid-year update: Charting GameSquare’s sharp business growth